Cayman Chemical Troglitazone, 97322-87-7, 10 mg

Supplier:  Cayman Chemical 7175010

Troglitazone is a TZD which was approved for the treatment of insulin resistance and hyperglycemia in Type II diabetes, under the trade name Resulin™, but was withdrawn from the market due to hepatotoxicity. Troglitazone is a potent and selective PPARγ agonist. The EC50 values for transactivation of human and mouse PPARγ in a cell-based assay are 0.55 and 0.78 µM, respectively.{10670} In the same assay system, no activation of PPARα and PPAR.delta. was observed at concentrations up to 10 µM. Troglitazone binds to the PPARγ ligand-binding domain (LBD) but fails to induce interaction of the PPARγ LBD with the transcriptional coactivators SRC-1, TIF2, AIB1, p300, or TRAP220.{8555} Troglitazone also induces cell cycle arrest and apoptosis in several cancer cell lines with an EC50 of 10 µM.{10669}

Catalog No. NC9237136